Your browser doesn't support javascript.
loading
Circulating microRNAs as potential biomarkers in triple-negative breast cancer: a translational research study of the NACATRINE trial.
Aguiar Freitas, Ana Julia; Nunes, Caroline Rocha; Mano, Max Senna; Causin, Rhafaela Lima; Calfa, Stéphanie; de Oliveira, Marco Antonio; Vidigal Santana, Iara Viana; Pádua Souza, Cristiano de; Chiquitelli Marques, Márcia Maria.
Afiliação
  • Aguiar Freitas AJ; Barretos Cancer Hospital, Molecular Oncology Research Center Barretos, São Paulo, BR - 14784-400, Brazil.
  • Nunes CR; Barretos Cancer Hospital, Molecular Oncology Research Center Barretos, São Paulo, BR - 14784-400, Brazil.
  • Mano MS; Grupo Oncoclínicas São Paulo, São Paulo, BR - 04538-132, Brazil.
  • Causin RL; Barretos Cancer Hospital, Molecular Oncology Research Center Barretos, São Paulo, BR - 14784-400, Brazil.
  • Calfa S; Barretos Cancer Hospital, Molecular Oncology Research Center Barretos, São Paulo, BR - 14784-400, Brazil.
  • de Oliveira MA; Barretos Cancer Hospital, Nucleus of Epidemiology & Biostatistics Barretos, São Paulo, BR - 14784-400, Brazil.
  • Vidigal Santana IV; Barretos Cancer Hospital, Pathology Department Barretos, São Paulo, BR - 14784-400, Brazil.
  • Pádua Souza C; Barretos Cancer Hospital, Barretos, São Paulo, Brazil - 14784-400, Brazil.
  • Chiquitelli Marques MM; Barretos Cancer Hospital, Molecular Oncology Research Center Barretos, São Paulo, BR - 14784-400, Brazil.
Future Oncol ; 20(1): 25-38, 2024 Jan.
Article em En | MEDLINE | ID: mdl-38131283
ABSTRACT
Liquid biopsy is increasingly vital in monitoring neoadjuvant breast cancer treatment. This study collected plasma samples at three time points from participants in the Neoadjuvant Carboplatin in Triple Negative Breast Cancer (NACATRINE), analyzing miRNA expression with NanoString's nCounter® Human v3 miRNA assay. In the carboplatin arm, four ct-miRNAs exhibited dynamic changes linked to pathologic complete response, with a combined area under the curve of 0.811. Similarly, the non-carboplatin arm featured four ct-miRNAs with an area under the curve of 0.843. These findings underscore the potential of ct-miRNAs as personalized tools in breast cancer treatment, assisting in predicting treatment response and assessing the risk of relapse. Integrating ct-miRNA analysis into clinical practice can optimize decisions and enhance patient outcomes.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: MicroRNAs / Neoplasias de Mama Triplo Negativas / MicroRNA Circulante Limite: Humans Idioma: En Revista: Future Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: MicroRNAs / Neoplasias de Mama Triplo Negativas / MicroRNA Circulante Limite: Humans Idioma: En Revista: Future Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido